Targets › LAG3
12 programs from 12 companies in 72 trials: 46 Phase 2, 20 Phase 1, 6 Phase 3; Oncology, Gastroenterology, Genitourinary; next expected readout Dec 2026.
[Lymphocyte activation gene 3 protein]: Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. (UniProt, P18627)
Open in Phaseline: the race on LAG3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Relatlimab Lymphocyte activation gene 3 protein inhibitor | LAG3 | Phase 3 | Non-small Cell Lung Cancer; Melanoma; Cancer; Urologic Neoplasms … | Dec 2026 |
| Regeneron Pharmaceuticals | Fianlimab (REGN3767) Lymphocyte activation gene 3 protein inhibitor | LAG3 | Phase 3 | Melanoma; Advanced Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Resectable Non-small Cell Lung Cancer … | Mar 2027 |
| Merck & Co. (MSD) | Favezelimab Lymphocyte activation gene 3 protein inhibitor | LAG3 | Phase 3 | Solid Tumors; Metastatic Urothelial Carcinoma; Small Cell Lung Carcinoma | May 2027 |
| Immutep S.A.S. | eftilagimod alfa Lymphocyte activation gene 3 protein vaccine antigen | LAG3 | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC); Neoadjuvant; Solid Tumors | Jun 2027 |
| University of Washington | Tuparstobart LAG-3 inhibitor monoclonal antibody | LAG3 | Phase 2 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 | Jan 2027 |
| University Health Network, Toronto | Opdualag (BMS-986213) Anti-LAG3/anti-PD-1 bispecific antibody | LAG3, PDCD1 | Phase 2 | Cutaneous Melanoma | Feb 2027 |
| Shanghai Henlius Biotech | HLX26 Anti-LAG-3 monoclonal antibody | LAG3 | Phase 2 | NSCLC Stage IV | Jul 2027 |
| Akeso | AK129 Bispecific antibody targeting LAG-3 and PD-1 | LAG3, PDCD1 | Phase 1 | Advanced Malignant Tumors(Stage IA-IB); Non-small Cell Lung Cancer Stage IIIB/IV; Classic Hodgkin Lymphoma | Dec 2026 |
| Roche | RO7247669 Anti-PD-1 and anti-LAG-3 bispecific antibody | PDCD1, LAG3 | Phase 1 | Solid Tumors | Jun 2027 |
| Shenyang Sunshine Pharmaceutical | SSGJ-709 Bispecific antibody targeting PD-1 and LAG-3 | PDCD1, LAG3 | Phase 1 | Advanced Malignant Tumors | Sep 2027 |
| Australian & New Zealand Children's Haematology/Oncology Group | Opdualag PD-1 and LAG-3 inhibitor combination | PDCD1, LAG3 | Phase 1 | Childhood Cancer | Dec 2030 |
| University Medical Center Groningen | 89Zr-DFO-REGN3767 Anti-LAG-3 PET imaging tracer | LAG3 | Phase 1 | Metastatic Solid Tumor | – |
Melanoma (9) Non-small Cell Lung Cancer (3) Solid Tumors (3) Head and Neck Squamous Cell Carcinoma (HNSCC) (2) Advanced Melanoma (2) Renal Cell Carcinoma (2) Colorectal Cancer (2) Basal Cell Carcinoma (2) Cutaneous Melanoma (2) Advanced Non-Small Cell Lung Cancer (1) Resectable Non-small Cell Lung Cancer (1) Advanced Malignancies (1)
antibody (5), small molecule (4), mixed (3)
Regeneron Pharmaceuticals (1) Merck & Co. (MSD) (1) Bristol-Myers Squibb (1) Roche (1) Immutep S.A.S. (1) Akeso (1) University Health Network, Toronto (1) Shenyang Sunshine Pharmaceutical (1) University Medical Center Groningen (1) University of Washington (1) Australian & New Zealand Children's Haematology/Oncology Group (1) Shanghai Henlius Biotech (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.